BBIO Q4 2023 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-6.7% YoY

Gross Profit

$1M65.7% margin

Operating Income

-$177M-10167.1% margin

Net Income

-$168M-9636.0% margin

EPS (Diluted)

$-0.96

QoQ Revenue Growth

-57.3%

Cash Flow

Operating Cash Flow

-$125M

Free Cash Flow

-$125M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$546M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.4B

Cash & Equivalents

$376M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-6.7%
Gross Profit	$1M	$1M	-6.2%
Operating Income	-$177M	-$129M	-37.3%
Net Income	-$168M	-$138M	-22.2%